Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Average Target Price of $7.50

Key Points

• Analyst sentiment is mixed: Seven brokerages give Cardiff Oncology a consensus “Hold” rating—three buys, three holds and one sell—with an average 1-year price target of $7.50.
• The stock traded at $0.80, near its 1-year low of $0.75 and well below its 1-year high of $3.31. Institutional investors and hedge funds own 16.29% of shares.
• Cardiff Oncology reported a quarterly loss of $0.14 per share, missing estimates of $0.12, while revenue of $0.10 million exceeded estimates. The clinical-stage biotech is developing onvansertib, a targeted cancer therapy.

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of analysts have weighed in on the company. William Blair downgraded Cardiff Oncology from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 11th. Weiss Ratings downgraded Cardiff Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 23rd. HC Wainwright upgraded Cardiff Oncology from a "neutral" rating to a "buy" rating in a research report on Tuesday, September 15th. Finally, Wall Street Zen raised Cardiff Oncology from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th.

Institutional Trading of Cardiff Oncology

Several large investors have recently modified their holdings of CRDF. BlackRock Inc. acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $1,265,000. GoalVest Advisory LLC acquired a new stake in Cardiff Oncology in the third quarter worth $832,000. Flputnam Investment Management Co. acquired a new stake in Cardiff Oncology in the second quarter worth $322,000. X Square Capital LLC bought a new stake in Cardiff Oncology in the second quarter valued at $267,000. Finally, GSA Capital Partners LLP bought a new stake in Cardiff Oncology in the second quarter valued at $225,000. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Stock Up 5.3%

Shares of CRDF stock traded up $0.04 during mid-day trading on Friday, reaching $0.80. 345,291 shares of the stock traded hands, compared to its average volume of 416,305. The stock's fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.40. Cardiff Oncology has a 1-year low of $0.75 and a 1-year high of $3.31. The company has a market cap of $61.87 million, a price-to-earnings ratio of -1.33 and a beta of 1.57.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts anticipate that Cardiff Oncology will post -0.60 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company's lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.